{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T13:07:49Z","timestamp":1742389669315,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T00:00:00Z","timestamp":1651881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T00:00:00Z","timestamp":1651881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00520-022-07102-6","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T12:05:08Z","timestamp":1651925108000},"page":"6775-6783","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6865-0366","authenticated-orcid":false,"given":"Yu","family":"Kondo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Tachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayoshi","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahito","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Teramachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,7]]},"reference":[{"key":"7102_CR1","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ et al (2015) Recommendations for the use of WBC Growth Factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33:3199\u20133212. https:\/\/doi.org\/10.1200\/JCO.2015.62.3488","journal-title":"J Clin Oncol"},{"key":"7102_CR2","unstructured":"NCCN (2021) NCCN practice guidelines in oncology. Hematopoietic Growth Factors 2021 ver. 4. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf. Accessed Jan 15 2022"},{"key":"7102_CR3","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M et al (2016) Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol 27:v111\u2013v118. https:\/\/doi.org\/10.1093\/annonc\/mdw325","journal-title":"Ann Oncol"},{"key":"7102_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404. https:\/\/doi.org\/10.1186\/1471-2407-11-404","journal-title":"BMC Cancer"},{"key":"7102_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/s0140-6736(14)60845-x","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665\u2013673. https:\/\/doi.org\/10.1016\/s0140-6736(14)60845-x","journal-title":"Lancet"},{"key":"7102_CR6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.lungcan.2016.07.019","volume":"99","author":"K Yoh","year":"2016","unstructured":"Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N et al (2016) A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer 99:186\u2013193. https:\/\/doi.org\/10.1016\/j.lungcan.2016.07.019","journal-title":"Lung Cancer"},{"key":"7102_CR7","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.4143\/crt.2015.401","volume":"48","author":"K Park","year":"2016","unstructured":"Park K, Kim JH, Cho EK, Kang JH, Shih JY, Zimmermann AH et al (2016) East Asian subgroup analysis of a randomized, double-blind, phase 3 study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small cell lung cancer following disease progression after one prior platinum-based therapy (REVEL). Cancer Res Treat 48:1177\u20131186. https:\/\/doi.org\/10.4143\/crt.2015.401","journal-title":"Cancer Res Treat"},{"key":"7102_CR8","unstructured":"JLCS (2021) Guidelines for diagnosis and treatment of lung cancer\/malignant pleural mesothelioma\/thymic tumor (in Japanese). https:\/\/www.haigan.gr.jp\/guideline\/2021\/. Accessed Apr 9 2022"},{"key":"7102_CR9","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1200\/JCO.2012.48.3644","volume":"31","author":"MJ Aarts","year":"2013","unstructured":"Aarts MJ, Grutters JP, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM et al (2013) Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. J Clin Oncol 31:4283\u20134289. https:\/\/doi.org\/10.1200\/JCO.2012.48.3644","journal-title":"J Clin Oncol"},{"key":"7102_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/030089160909500214","volume":"95","author":"M Danova","year":"2009","unstructured":"Danova M, Chiroli S, Rosti G, Doan QV (2009) Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori 95:219\u2013226","journal-title":"Tumori"},{"key":"7102_CR11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40273-016-0474-0","volume":"35","author":"K Fust","year":"2017","unstructured":"Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R et al (2017) Cost-effectiveness analysis of prophylaxis treatment strategies to reduce the incidence of febrile neutropenia in patients with early-stage breast cancer or non-Hodgkin lymphoma. Pharmacoeconomics 35:425\u2013438. https:\/\/doi.org\/10.1007\/s40273-016-0474-0","journal-title":"Pharmacoeconomics"},{"key":"7102_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3111\/13696998.2013.844160","volume":"17","author":"G Hill","year":"2014","unstructured":"Hill G, Barron R, Fust K, Skornicki ME, Taylor DC, Weinstein MC et al (2014) Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin\u2019s lymphoma: cost-effectiveness analyses. J Med Econ 17:32\u201342. https:\/\/doi.org\/10.3111\/13696998.2013.844160","journal-title":"J Med Econ"},{"key":"7102_CR13","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1691\/ph.2021.1031","volume":"76","author":"T Ichimura","year":"2021","unstructured":"Ichimura T, Nomura H, Shimizu H, Machida Y, Suzuki K (2021) Cost-effectiveness of primary prophylaxis of febrile neutropenia with pegfilgrastim in docetaxel, cisplatin and 5-fluorouracil therapy for esophageal cancer. Pharmazie 76:450\u2013454. https:\/\/doi.org\/10.1691\/ph.2021.1031","journal-title":"Pharmazie"},{"key":"7102_CR14","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1093\/jnci\/djt182","volume":"105","author":"N Lathia","year":"2013","unstructured":"Lathia N, Isogai PK, De Angelis C, Smith TJ, Cheung M, Mittmann N et al (2013) Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients. J Natl Cancer Inst 105:1078\u20131085. https:\/\/doi.org\/10.1093\/jnci\/djt182","journal-title":"J Natl Cancer Inst"},{"key":"7102_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1185\/03007990802636817","volume":"25","author":"G Lyman","year":"2009","unstructured":"Lyman G, Lalla A, Barron R, Dubois RW (2009) Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin\u2019s lymphoma receiving CHOP-21 in United States. Curr Med Res Opin 25:401\u2013411. https:\/\/doi.org\/10.1185\/03007990802636817","journal-title":"Curr Med Res Opin"},{"key":"7102_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148901","volume":"11","author":"XJ Wang","year":"2016","unstructured":"Wang XJ, Tang T, Farid M, Quek R, Tao M, Lim ST et al (2016) Routine primary prophylaxis for febrile neutropenia with biosimilar granulocyte colony-stimulating factor (Nivestim) or pegfilgrastim is cost effective in non-Hodgkin lymphoma patients undergoing curative-intent R-CHOP chemotherapy. PLoS ONE 11:e0148901. https:\/\/doi.org\/10.1371\/journal.pone.0148901","journal-title":"PLoS ONE"},{"key":"7102_CR17","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1200\/JCO.2005.05.645","volume":"23","author":"OA Clark","year":"2005","unstructured":"Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23:4198\u20134214. https:\/\/doi.org\/10.1200\/JCO.2005.05.645","journal-title":"J Clin Oncol"},{"key":"7102_CR18","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158\u20133167. https:\/\/doi.org\/10.1200\/JCO.2006.08.8823","journal-title":"J Clin Oncol"},{"key":"7102_CR19","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.jtho.2019.07.007","volume":"14","author":"SC Yang","year":"2019","unstructured":"Yang SC, Kuo CW, Lai WW, Lin CC, Su WC, Chang SM et al (2019) Dynamic changes of health utility in lung cancer patients receiving different treatments: a 7-year follow-up. J Thorac Oncol 14:1892\u20131900. https:\/\/doi.org\/10.1016\/j.jtho.2019.07.007","journal-title":"J Thorac Oncol"},{"key":"7102_CR20","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1111\/ajco.12477","volume":"13","author":"B Nafees","year":"2017","unstructured":"Nafees B, Lloyd AJ, Dewilde S, Rajan N, Lorenzo M (2017) Health state utilities in non-small cell lung cancer: an international study. Asia Pac J Clin Oncol 13:e195\u2013e203. https:\/\/doi.org\/10.1111\/ajco.12477","journal-title":"Asia Pac J Clin Oncol"},{"key":"7102_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1477-7525-6-84","volume":"6","author":"B Nafees","year":"2008","unstructured":"Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J (2008) Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 6:84. https:\/\/doi.org\/10.1186\/1477-7525-6-84","journal-title":"Health Qual Life Outcomes"},{"key":"7102_CR22","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.1007\/s00520-020-05317-z","volume":"28","author":"N Kasahara","year":"2020","unstructured":"Kasahara N, Sunaga N, Kuwako T, Naruse I, Imai H, Jingu A et al (2020) Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study. Support Care Cancer 28:4825\u20134831. https:\/\/doi.org\/10.1007\/s00520-020-05317-z","journal-title":"Support Care Cancer"},{"key":"7102_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000335604","volume":"58","author":"D Weycker","year":"2012","unstructured":"Weycker D, Edelsberg J, Kartashov A, Barron R, Lyman G (2012) Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. Chemotherapy 58:8\u201318. https:\/\/doi.org\/10.1159\/000335604","journal-title":"Chemotherapy"},{"key":"7102_CR24","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/j.cllc.2017.10.013","volume":"19","author":"J Cupp","year":"2018","unstructured":"Cupp J, Culakova E, Poniewierski MS, Dale DC, Lyman GH, Crawford J (2018) Analysis of factors associated with in-hospital mortality in lung cancer chemotherapy patients with neutropenia. Clin Lung Cancer 19:e163\u2013e169. https:\/\/doi.org\/10.1016\/j.cllc.2017.10.013","journal-title":"Clin Lung Cancer"},{"key":"7102_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s12029-016-9885-6","volume":"48","author":"I Tsukiyama","year":"2017","unstructured":"Tsukiyama I, Ejiri M, Yamamoto Y, Nakao H, Yoneda M, Matsuura K et al (2017) A cost-effectiveness analysis of gemcitabine plus cisplatin versus gemcitabine alone for treatment of advanced biliary tract cancer in Japan. J Gastrointest Cancer 48:326\u2013332. https:\/\/doi.org\/10.1007\/s12029-016-9885-6","journal-title":"J Gastrointest Cancer"},{"key":"7102_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/intqhc\/mzt081","volume":"26","author":"T Morishima","year":"2014","unstructured":"Morishima T, Lee J, Otsubo T, Imanaka Y (2014) Association of healthcare expenditures with aggressive versus palliative care for cancer patients at the end of life: a cross-sectional study using claims data in Japan. Int J Qual Health Care 26:79\u201386. https:\/\/doi.org\/10.1093\/intqhc\/mzt081","journal-title":"Int J Qual Health Care"},{"key":"7102_CR27","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00520-013-2067-1","volume":"22","author":"A Chan","year":"2014","unstructured":"Chan A, Wong QX, Ali MK, Wong M, Hsu LY (2014) Clinical efficacy of adjunctive G-CSF on solid tumor and lymphoma patients with established febrile neutropenia. Support Care Cancer 22:1105\u20131112. https:\/\/doi.org\/10.1007\/s00520-013-2067-1","journal-title":"Support Care Cancer"},{"key":"7102_CR28","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1111\/cas.13736","volume":"109","author":"I Tsukiyama","year":"2018","unstructured":"Tsukiyama I, Hasegawa S, Ikeda Y, Takeuchi M, Tsukiyama S, Kurose Y et al (2018) Cost-effectiveness of aprepitant in Japanese patients treated with cisplatin-containing highly emetogenic chemotherapy. Cancer Sci 109:2881\u20132888. https:\/\/doi.org\/10.1111\/cas.13736","journal-title":"Cancer Sci"},{"key":"7102_CR29","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hec.1481","volume":"19","author":"T Shiroiwa","year":"2010","unstructured":"Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K (2010) International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 19:422\u2013437. https:\/\/doi.org\/10.1002\/hec.1481","journal-title":"Health Econ"},{"key":"7102_CR30","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2217\/fon-2018-0878","volume":"15","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Wang J, Otto GP, Gattu S, Krendyukov A (2019) Safety analysis of proposed pegfilgrastim biosimilar in phase I and phase III studies. Future Oncol 15:1313\u20131322. https:\/\/doi.org\/10.2217\/fon-2018-0878","journal-title":"Future Oncol"},{"key":"7102_CR31","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.2217\/fon-2016-0016","volume":"12","author":"N Harbeck","year":"2016","unstructured":"Harbeck N, Lipatov O, Frolova M, Udovitsa D, Topuzov E, Ganea-Motan DE et al (2016) Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Future Oncol 12:1359\u20131367. https:\/\/doi.org\/10.2217\/fon-2016-0016","journal-title":"Future Oncol"},{"key":"7102_CR32","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1634\/theoncologist.2016-0011","volume":"21","author":"K Blackwell","year":"2016","unstructured":"Blackwell K, Donskih R, Jones CM, Nixon A, Vidal MJ, Nakov R et al (2016) A comparison of proposed biosimilar LA-EP2006 and reference pegfilgrastim for the prevention of neutropenia in patients with early-stage breast cancer receiving myelosuppressive adjuvant or neoadjuvant chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a phase III, randomized, double-blind trial. Oncologist 21:789\u2013794. https:\/\/doi.org\/10.1634\/theoncologist.2016-0011","journal-title":"Oncologist"},{"key":"7102_CR33","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1111\/bcp.13731","volume":"84","author":"R Nakov","year":"2018","unstructured":"Nakov R, Gattu S, Wang J, Velinova M, Schaffar G, Skerjanec A (2018) Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects. Br J Clin Pharmacol 84:2790\u20132801. https:\/\/doi.org\/10.1111\/bcp.13731","journal-title":"Br J Clin Pharmacol"},{"key":"7102_CR34","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1182\/blood.V130.Suppl_1.3568.3568","volume":"130","author":"C Waller","year":"2017","unstructured":"Waller C, Ranganna GM, Pennella E, Mattano LA, Loa CC, Donnelly C et al (2017) Comparison of immunogenicity between the proposed pegfilgrastim biosimilar MYL-1401H and reference pegfilgrastim. Blood 130:3568\u20133568. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.3568.3568","journal-title":"Blood"},{"key":"7102_CR35","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00277-019-03639-5","volume":"98","author":"CF Waller","year":"2019","unstructured":"Waller CF, Ranganna GM, Pennella EJ, Blakeley C, Bronchud MH, Mattano LA Jr et al (2019) Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia. Ann Hematol 98:1217\u20131224. https:\/\/doi.org\/10.1007\/s00277-019-03639-5","journal-title":"Ann Hematol"},{"key":"7102_CR36","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s00432-018-2643-3","volume":"144","author":"CF Waller","year":"2018","unstructured":"Waller CF, Tiessen RG, Lawrence TE, Shaw A, Liu MS, Sharma R et al (2018) A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim. J Cancer Res Clin Oncol 144:1087\u20131095. https:\/\/doi.org\/10.1007\/s00432-018-2643-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"7102_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1586\/14737167.8.2.165","volume":"8","author":"SD Grosse","year":"2008","unstructured":"Grosse SD (2008) Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 8:165\u2013178. https:\/\/doi.org\/10.1586\/14737167.8.2.165","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"7102_CR38","unstructured":"NICE (2004) Guide to the methods of technological appraisal. Ref: N0514. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/191504\/NICE_guide_to_the_methods_of_technology_appraisal.pdf. Accessed Jan 16 2022"},{"key":"7102_CR39","unstructured":"NICE (2008) Guide to the methods of technological appraisal. Ref: N1618. https:\/\/heatinformatics.com\/sites\/default\/files\/images-videosFileContent\/UK%20NHS_NICE%20HTA%202008.pdf. Accessed Jan 16 2022"},{"key":"7102_CR40","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1017\/s0266462320000264","volume":"36","author":"T Shiroiwa","year":"2020","unstructured":"Shiroiwa T (2020) Cost-effectiveness evaluation for pricing medicines and devices: a new value-based price adjustment system in Japan. Int J Technol Assess Health Care 36:270\u2013276. https:\/\/doi.org\/10.1017\/s0266462320000264","journal-title":"Int J Technol Assess Health Care"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07102-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-07102-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-07102-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T05:09:02Z","timestamp":1655788142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-07102-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,7]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["7102"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-07102-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2022,5,7]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consented to publish this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}